{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:57:02Z","timestamp":1769821022739,"version":"3.49.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Due to the lack of large-scale clinical trials, the treatment strategies of small bowel adenocarcinoma (SBA) are controversial, especially for stage II patients. According to the National Comprehensive Cancer Network (NCCN) guideline, few lymph nodes (LNs) examined (&amp;lt;5 for duodenum or &amp;lt;8 for jejunal\/ileal primary location) are one of the high-risk features for stage II patients, for whom adjuvant chemotherapy is recommended. This consensus is originally drawn from data in the Surveillance, Epidemiology, and End Results Database (SEER) between 1988 and 2010. However, the surgical modalities and chemotherapy strategies changed a lot after 2004 for SBA patients. The previous data may not represent a true picture of current therapeutics. Thus, we reanalyzed the SEER database and updated the cutoff point of LN numbers resected with respect to cancer-specific survival (CSS) using the latest SEER information.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with stage II SBA and who underwent curative surgery between 2004 and 2018 were extracted from the SEER database. CSS was calculated using the Kaplan\u2013Meier method and compared by log-rank test. Maximum survival differences based on total LNs examined for duodenal and jejunoileal tumors were determined separately with the cut-point analysis and maximum log-rank \u03c7<jats:sup>2<\/jats:sup> statistic. A nomogram model was constructed based on the multivariate Cox analysis to predict 5\u2010 and 10\u2010year CSS and was then validated with an internal cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 935 stage II SBA patients met the inclusion criteria. The greatest difference in survival was found in patients who had removal of at least 5 LNs for duodenal and 12 LNs for jejunoileal tumors. Multivariate Cox analysis showed that age, T stage, histology grade, primary site, and LN numbers were independent prognostic factors for survival. The C index of nomogram model was 0.701 (95% CI, 0.661\u20130.741, p &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The number of LNs harvested is an important prognostic factor for survival in stage II SBA patients. LN number examined &amp;lt;5 remains a high-risk factor for duodenum, but the cutoff point for jejunal\/ileal tumors should rise from 8 to 12. Appropriate radical lymphadenectomy should be performed in stage II SBA surgery.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.865745","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:23:16Z","timestamp":1648632196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic Value of Lymph Node Evaluation in Stage II Small Bowel Adenocarcinoma: An Updated Analysis of Surveillance, Epidemiology, and End Results Database"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiale","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","article-title":"Small Bowel Adenocarcinoma: Epidemiology, Risk Factors, Diagnosis and Treatment","volume":"46","author":"Aparicio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40605.x","article-title":"Pathogenesis and Risk Factors of Small Bowel Adenocarcinoma: A Colorectal Cancer Sibling","volume":"100","author":"Delaunoit","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.surge.2014.02.003","article-title":"Malignant Tumours of the Small Intestine","volume":"12","author":"Reynolds","year":"2014","journal-title":"Surgeon"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7344","article-title":"Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations","volume":"17","author":"Pedersen","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25324","article-title":"Prognostic Value of Lymph Node Evaluation in Small Bowel Adenocarcinoma: Analysis of the Surveillance, Epidemiology, and End Results Database","volume":"116","author":"Overman","year":"2010","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.03.048","article-title":"Prognostic Relevance of Lymph Node Ratio and Total Lymph Node Count for Small Bowel Adenocarcinoma","volume":"158","author":"Tran","year":"2015","journal-title":"Surgery"},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD005202","DOI":"10.1002\/14651858.CD005202.pub2","article-title":"Adjuvant Chemotherapy for Small Intestine Adenocarcinoma","volume":"3","author":"Singhal","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","article-title":"FDA Drug Approval Summaries: Oxaliplatin","volume":"9","author":"Ibrahim","year":"2004","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23822","article-title":"Chemotherapy With 5-Fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma","volume":"113","author":"Overman","year":"2008","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0003","article-title":"Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer","volume":"17","author":"Strickler","year":"2012","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/107327480501200205","article-title":"Targeted Therapies in the Treatment of Colorectal Cancers","volume":"12","author":"Alekshun","year":"2005","journal-title":"Cancer Control"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of Using \u201cOptimal\u201d Cutpoints in the Evaluation of Prognostic Factors","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1514353","article-title":"Prognostic Subgroups Among Patients With Stage II Colon Cancer","volume":"374","author":"Boland","year":"2016","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/codi.14994","article-title":"Postoperative Chemotherapy Improves Survival in Patients With Resected High-Risk Stage II Colorectal Cancer: Results of a Systematic Review and Meta-Analysis","volume":"22","author":"Simillis","year":"2020","journal-title":"Colorectal Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08926-4","article-title":"Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas","volume":"28","author":"Vanoli","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.865745\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:23:20Z","timestamp":1648632200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.865745\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":15,"alternative-id":["10.3389\/fonc.2022.865745"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.865745","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"article-number":"865745"}}